Glucagon-like peptide 1, glucose-dependent insulinotropic peptide, and dual- Glucagon-like peptide 1/glucose-dependent insulinotropic peptide receptor agonists show good effects in animal models of Parkinson’s disease. The gene discussed is GCG; the disease is Parkinson disease.